Harvard Business Review
SEPTEMBER 12, 2012
Equating "innovative" with new molecules misses the point: to develop clinically superior new medicines. The apparent business model of Big Pharma emphasizes the billions spent at great risk to find "innovative" and "breakthrough" new molecules that must be priced high to recover research costs that have become "unsustainable."
Harvard Business Review
NOVEMBER 11, 2013
In addition to disclosing conflicts of interest, physicians attest to participating in the QIP and report their roles (see Table 2 ). From January 2010, when the quality review board became operational, to December 2012, 230 QIPs were reviewed and 168 (73%) of them were approved for Part IV MOC. Leading Health Care Innovation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
FEBRUARY 3, 2017
By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible.
Harvard Business Review
FEBRUARY 24, 2017
While concerns about conflicts of interest regarding President Trump’s business holdings have received a lot of attention, resulting in proposed legislation to end loopholes for the commander in chief , there has been much less discussion of another source of conflicting interests: the investments of members of Congress.
Harvard Business Review
MARCH 2, 2017
On February 3 President Trump issued an executive order directing the Treasury Department to conduct a sweeping review of financial regulation, including Dodd-Frank , the financial reform bill passed, in 2010, as part of the Obama administration’s response to the 2008 financial crisis and subsequent recession.
Expert insights. Personalized for you.
15 
Let's personalize your content